FDA Approves Dupilumab (Dupixent, Sanofi & Regeneron) for CSU
Add chronic spontaneous urticaria (CSU) to the list of U.S. Food and Drug Administration (FDA) approvals for dupilumab (Dupixent, Sanofi & Regeneron).
Day: April 18, 2025
Add chronic spontaneous urticaria (CSU) to the list of U.S. Food and Drug Administration (FDA) approvals for dupilumab (Dupixent, Sanofi & Regeneron).